DE10199003I2 - - Google Patents

Info

Publication number
DE10199003I2
DE10199003I2 DE2001199003 DE10199003C DE10199003I2 DE 10199003 I2 DE10199003 I2 DE 10199003I2 DE 2001199003 DE2001199003 DE 2001199003 DE 10199003 C DE10199003 C DE 10199003C DE 10199003 I2 DE10199003 I2 DE 10199003I2
Authority
DE
Germany
Prior art keywords
group
substituted
compounds
unsubstituted
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE2001199003
Other languages
German (de)
English (en)
Other versions
DE10199003I1 (de
Inventor
Richard Mark Hindley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27263577&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10199003(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB878720825A external-priority patent/GB8720825D0/en
Priority claimed from GB878727987A external-priority patent/GB8727987D0/en
Priority claimed from GB888802454A external-priority patent/GB8802454D0/en
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Application granted granted Critical
Publication of DE10199003I1 publication Critical patent/DE10199003I1/de
Publication of DE10199003I2 publication Critical patent/DE10199003I2/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
DE2001199003 1987-09-04 1988-08-26 Substituierte Thiazolidinionderivate Granted DE10199003I1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB878720825A GB8720825D0 (en) 1987-09-04 1987-09-04 Compounds
GB878727987A GB8727987D0 (en) 1987-11-30 1987-11-30 Novel compounds
GB888802454A GB8802454D0 (en) 1988-02-04 1988-02-04 Compounds

Publications (2)

Publication Number Publication Date
DE10199003I1 DE10199003I1 (de) 2003-06-12
DE10199003I2 true DE10199003I2 (instruction) 2003-09-18

Family

ID=27263577

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2001199003 Granted DE10199003I1 (de) 1987-09-04 1988-08-26 Substituierte Thiazolidinionderivate
DE3856378T Expired - Lifetime DE3856378T2 (de) 1987-09-04 1988-08-26 Substituierte Thiazolidindionderivate

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE3856378T Expired - Lifetime DE3856378T2 (de) 1987-09-04 1988-08-26 Substituierte Thiazolidindionderivate

Country Status (18)

Country Link
US (1) US5002953A (instruction)
EP (2) EP0306228B1 (instruction)
JP (6) JP2614497B2 (instruction)
KR (1) KR0164207B1 (instruction)
AT (1) ATE186724T1 (instruction)
AU (1) AU611938B2 (instruction)
CA (1) CA1328452C (instruction)
CZ (1) CZ391691A3 (instruction)
DE (2) DE10199003I1 (instruction)
DK (2) DK175176B1 (instruction)
ES (1) ES2137915T3 (instruction)
GR (1) GR3031873T3 (instruction)
IE (1) IE20000683A1 (instruction)
LU (1) LU90711I2 (instruction)
NL (1) NL300034I2 (instruction)
NZ (1) NZ226027A (instruction)
PT (1) PT88410B (instruction)
SG (1) SG59988A1 (instruction)

Families Citing this family (274)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB8919417D0 (en) 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
US5053420A (en) * 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
GB9017218D0 (en) * 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
GB9023584D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
ATE144142T1 (de) * 1991-01-10 1996-11-15 Transcend Therapeutics Inc Verwendung von thiazolidin-4-carboxylatderivaten zur behandlung von lungenerkrankungen
US5747459A (en) * 1991-02-04 1998-05-05 Nestec, Ltd. Method for insuring adequate intracellular glutathione in tissue
JP3053490B2 (ja) * 1991-02-25 2000-06-19 杏林製薬株式会社 チアゾリジン−２，４−ジオン誘導体とその塩及び製造法
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
US5589492A (en) * 1992-04-10 1996-12-31 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of Type-II diabetes
WO1993021166A1 (en) * 1992-04-10 1993-10-28 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type ii-diabetes
US5430045A (en) * 1992-04-23 1995-07-04 Free Radical Sciences, Inc. Method of reducing or preventing bone marrow hypoplasia
US6048883A (en) * 1992-07-03 2000-04-11 Smithkline Beecham P.L.C. Heterocyclic compounds as pharmaceutical
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
US5306724A (en) * 1992-08-17 1994-04-26 Clintec Nutrition Company Method for preventing and treating atherosclerosis
ATE185564T1 (de) * 1992-08-31 1999-10-15 Sankyo Co Oxazolidin-derivate mit antidiabetika und anti- fettleibigkeit-eigenschaften, ihre herstellung und therapeutische verwendung
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
US5521202A (en) * 1993-04-07 1996-05-28 Taiho Pharmaceutical Co., Ltd. Thiazolidine derivatives and pharmaceutical compositions containing the same
GB9308487D0 (en) * 1993-04-23 1993-06-09 Smithkline Beecham Plc Novel compounds
GB9311661D0 (en) * 1993-06-05 1993-07-21 Smithkline Beecham Plc Novel compounds
GB9311644D0 (en) * 1993-06-05 1993-07-21 Smithkline Beecham Plc Novel compounds
GB9315148D0 (en) * 1993-07-22 1993-09-08 Smithkline Beecham Plc Novel compounds
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
CZ283339B6 (cs) * 1993-09-15 1998-03-18 Sankyo Company Limited Použití thiazolidinových derivátů pro výrobu léčivého přípravku pro léčení zhoršené tolerance glukosy pro zabránění nebo zpoždění nástupu diabetes mellitus nezávislé na inzulinu
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5447712A (en) * 1993-12-09 1995-09-05 Free Radical Sciences Method of reducing cyclophosphamide induced hemorrhagic cystitis
US5480896A (en) * 1994-01-27 1996-01-02 American Home Products Corporation Aralkyl-1,2,4-oxadiazolidine-3,5-diones as antihyperglycemic agents
EP0777469A1 (en) * 1994-02-10 1997-06-11 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
CA2146701A1 (en) * 1994-04-11 1995-10-12 Takashi Fujita Heterocyclic compounds having anti-diabetic activity, their preparation and their use
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US5703096A (en) 1994-10-07 1997-12-30 Sankyo Company, Limited Oxime derivatives, their preparation and their therapeutic use
US5436373A (en) * 1994-10-26 1995-07-25 Elf Atochem North America, Inc. Process for the preparation of N-benzyl-N-organoaminoalkanol
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
US5827865A (en) * 1995-03-09 1998-10-27 Smithkline Beecham P.L.C. Heterocyclic compounds as pharmaceutical
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
RU2158607C2 (ru) * 1995-07-03 2000-11-10 Санкио Компани Лимитед Лечение артериосклероза и ксантомы
US6020382A (en) * 1996-02-02 2000-02-01 Merck & Co., Inc. Method of treating diabetes and related disease states
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US5847008A (en) * 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US6090836A (en) * 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
DK0916651T3 (da) * 1996-04-04 2003-12-01 Sankyo Co Phenylalkylcarboxylsyrederivater
EP0801063B1 (en) * 1996-04-09 2003-01-15 Dr. Reddy's Laboratories Ltd. Thiazolidinedione derivatives having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5889032A (en) * 1996-05-06 1999-03-30 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973850B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
WO1997043283A1 (de) * 1996-05-16 1997-11-20 Boehringer Mannheim Gmbh Neues verfahren zur herstellung von troglitazone
CA2257284C (en) * 1996-05-31 2005-10-04 Sankyo Company Limited Remedy for autoimmune diseases
US6372750B2 (en) * 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
AU744518B2 (en) * 1996-07-01 2002-02-28 Dr. Reddy's Laboratories Limited Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
CN1221417A (zh) * 1996-07-26 1999-06-30 雷迪博士研究基金会 具有抗糖尿病、降低血脂、抗高血压性能的噻唑烷二酮化合物,其制备方法及其药物组合物
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
UY24886A1 (es) * 1997-02-18 2001-08-27 Smithkline Beecham Plc Tiazolidindiona
AU774839B2 (en) * 1997-02-18 2004-07-08 Smithkline Beecham Plc Process for the preparation of substituted thiazolidinedione
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
DE19711616A1 (de) 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6011036A (en) * 1997-04-15 2000-01-04 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them
US6011031A (en) * 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
AU8539298A (en) * 1997-06-18 1999-01-04 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and sulphonylurea
NZ501260A (en) * 1997-06-18 2002-09-27 Smithkline Beecham P Treatment of diabetes with thiazolidinedione and metformin
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
AU738134B2 (en) 1997-10-02 2001-09-06 Sankyo Company Limited Amidocarboxylic acid derivatives
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
US20010031776A1 (en) * 1997-10-13 2001-10-18 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
GB9721693D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
US7091359B2 (en) 1997-11-04 2006-08-15 Smithkline Beecham Plc Process for the preparation of thiazolidinedione derivatives
GB9723295D0 (en) * 1997-11-04 1998-01-07 Smithkline Beecham Plc Novel process
HUP9902721A2 (hu) 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
ATE212991T1 (de) * 1997-12-02 2002-02-15 Reddy Research Foundation Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
AU7109798A (en) * 1997-12-02 1998-10-30 Dr. Reddy's Research Foundation Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypol ipidemia and antihypertensive properties
WO1999030739A1 (fr) * 1997-12-16 1999-06-24 Sankyo Company, Limited Remede contre la leucemie
GB9726563D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
EP1087963B1 (en) 1998-06-19 2004-08-25 Chiron Corporation Inhibitors of glycogen synthase kinase 3
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
US6613785B2 (en) 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
DK1098639T3 (da) * 1998-07-21 2005-06-13 Smithkline Beecham Plc Anvendelse af glucoseoptagelsesforstærkeren rosiglitazon til reduktion af iskæmiinduceret apoptose af pankreatiske beta-celler, endotelceller og neuronale celler
IN187716B (instruction) * 1998-09-14 2002-06-15 Reddy Research Foundation
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
PL347634A1 (en) 1998-11-12 2002-04-22 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
AR023699A1 (es) 1998-11-12 2002-09-04 Smithkline Beecham Corp Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
CA2350599A1 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
AU3073700A (en) * 1999-01-19 2000-08-07 Sankyo Company Limited Troglitazone-containing medicinal compositions for inhibiting apoptosis
GB9909075D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
JP2002543077A (ja) 1999-04-23 2002-12-17 スミスクライン ビーチャム パブリック リミテッド カンパニー ５−［４−［２−（ｎ−メチル−ｎ−（２−ピリジル）アミノ）エトキシ］ベンジル］チアゾリジン−２，４−ジオン，マレイン酸塩の多形体
EA004534B1 (ru) 1999-04-23 2004-06-24 Смитклайн Бичам Плс Новый фармацевтический препарат
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
AP1607A (en) * 1999-04-23 2006-05-03 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic.
EP1180520B1 (en) 1999-04-28 2007-06-20 Institute of Medicinal Molecular Design, Inc. Pyrimidine carboxylic acid derivatives
GB9913782D0 (en) * 1999-06-14 1999-08-11 Smithkline Beecham Plc Novel compounds
ES2277842T3 (es) * 1999-06-18 2007-08-01 MERCK & CO., INC. Derivados de ariltiazolidindiona y de ariloxazolidindiona.
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
KR20020022812A (ko) * 1999-08-17 2002-03-27 피터 기딩스 티아졸리딘디온 유도체를 함유하는 제약 조성물 및 그의제조 방법
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
AR028299A1 (es) 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
ES2156574B1 (es) * 1999-11-18 2002-02-01 Vita Invest Sa Nuevos derivados de tiazolidindiona como agentes antidiabeticos
CZ20021911A3 (cs) 1999-12-03 2002-10-16 Kyoto Pharmaceutical Industries, Ltd. Nové heterocyklické sloučeniny a jejich soli a jejich vyuľití v lékařství
HU225919B1 (en) * 1999-12-18 2007-12-28 Richter Gedeon Nyrt Thiazolidine-derivatives, process for their preparation pharmaceutical and intermediates
CA2397554C (en) 2000-01-21 2009-09-22 Novartis Ag Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
GB0006133D0 (en) * 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
US6768008B2 (en) * 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6958355B2 (en) 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
AU2001260615A1 (en) * 2000-05-25 2001-12-03 Yamanouchi Pharmaceutical Co..Ltd. Human pgc-1 promoter
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0019223D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
WO2002024689A1 (en) 2000-09-21 2002-03-28 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis
AU9123201A (en) * 2000-09-26 2002-04-08 Reddy S Res Foundation Novel polymorphic forms of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl) thiazolidine-2,4-dione maleate and process for their preparation
US7241895B2 (en) 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
GB0023971D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
GB0029125D0 (en) * 2000-11-29 2001-01-10 Specialistkliniken I Varberg H Novel treatment
ATE337313T1 (de) 2000-12-22 2006-09-15 Smithkline Beecham Plc 5-4'-2'-(n-methyl-n-(2-pyridyl)amino) ethoxy)benzyl)thiazolidin-2,4-dion mesylatsalz
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
WO2002051823A1 (en) 2000-12-26 2002-07-04 Torrent Pharmaceuticals Ltd Process for the preparation of rosiglitazone maleate
EP1695716A2 (en) * 2000-12-26 2006-08-30 Sankyo Company, Limited Medicinal compositions containing diuretics and insulin sensitizers
ES2174748B1 (es) * 2001-01-31 2003-09-16 Vita Lab Nueva sal de tiazolidindiona y sus polimorfos como agentes antidiabeticos y procedimiento para la obtencion de los mismos.
DE60231295D1 (de) * 2001-04-04 2009-04-09 Ortho Mcneil Janssen Pharm R und ppar modulatoren
US20060047000A1 (en) * 2001-04-24 2006-03-02 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
PL367676A1 (en) * 2001-05-29 2005-03-07 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic derivatives and medicinal use thereof
PL367639A1 (en) * 2001-05-29 2005-03-07 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic compound and medicinal use thereof
JP4152641B2 (ja) * 2001-08-07 2008-09-17 クラシエ製薬株式会社 チアゾリジン誘導体の副作用軽減剤
WO2003029251A1 (en) * 2001-09-28 2003-04-10 Biocon Limited Novel process for the synthesis of thiazolidinedione derivatives
GB0127805D0 (en) 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
WO2003050116A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
GB0129851D0 (en) * 2001-12-13 2002-01-30 Smithkline Beecham Plc Novel compounds
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129872D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130511D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002366812A1 (en) * 2001-12-20 2003-07-09 Teva Pharmaceutical Industries Ltd. Hydrogenation of precursors to thiazolidinedione antihyperglycemics
GB0130510D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003053962A1 (en) * 2001-12-20 2003-07-03 Smithkline Beecham Plc 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US7015345B2 (en) * 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
KR100450700B1 (ko) 2002-03-22 2004-10-01 주식회사종근당 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
US7041832B2 (en) * 2002-04-29 2006-05-09 Tava Pharmaceutical Industries, Ltd. Processes for preparing losartan and losartan potassium
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
EP1388352A1 (en) 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
JP4887139B2 (ja) 2003-03-25 2012-02-29 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
WO2004089945A1 (en) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Rosiglitazone derivatives as antidiabetic agents
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
WO2004106542A1 (ja) * 2003-05-29 2004-12-09 Sankyo Company, Limited インスリン抵抗性改善剤及びそのスクリーニング方法
EP1658283A2 (en) * 2003-05-30 2006-05-24 Ranbaxy Laboratories, Ltd. Substituted pyrrole derivatives and their use as hmg-co inhibitors
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
US7790736B2 (en) 2003-08-13 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1699777B1 (en) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005023803A1 (en) * 2003-09-10 2005-03-17 Biocon Limited Phosphoric acid salt of 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl] methyl]- 2,4-thiazolidinedione
US7625916B2 (en) * 2003-09-17 2009-12-01 Kaname Kawasugi Medicinal composition
EP1732513A2 (en) * 2003-12-31 2006-12-20 Alpharma, Inc. Rosiglitazone formulations
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
EP1709038A2 (en) * 2004-01-28 2006-10-11 Usv Limited A process for the preparation of 5- 4- 2- n-methyl -n-(2-pyridyl) amino ethoxy phenyl methyl thiaz olidine-2, 4-dione maleate
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
GB2410948A (en) * 2004-02-13 2005-08-17 Sandoz Ag Novel phosphoric acid salt of rosiglitazone
GB2421240A (en) * 2004-12-14 2006-06-21 Sandoz Ag Phosphoric acid salt of rosiglitazone
CN102134231B (zh) * 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
KR20070011329A (ko) * 2004-03-29 2007-01-24 상꾜 가부시키가이샤 인슐린 저항성 개선제를 함유하는 당뇨병 치료제
GB2413795A (en) * 2004-05-05 2005-11-09 Cipla Ltd Process for the preparation of rosiglitazone
EP1745043A1 (en) * 2004-05-12 2007-01-24 Medichem S.A. Process for the preparation of rosiglitazone
CZ296468B6 (cs) * 2004-06-10 2006-03-15 Zentiva, A. S. Sul kyseliny fosforecné s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionema zpusob její prípravy
TW200608967A (en) * 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
CZ297266B6 (cs) * 2004-09-10 2006-10-11 Zentiva, A. S. Zpusob prípravy rosiglitazonu
CZ297347B6 (cs) * 2004-09-21 2006-11-15 Zentiva, A. S. Zpusob prípravy rosiglitazonu
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
US20070190079A1 (en) * 2004-10-29 2007-08-16 Kalypsys, Inc. Methods for the selective modulation of ppar
US20060122232A1 (en) * 2004-12-06 2006-06-08 Development Center For Biotechnology 4-Hydroxyfuroic acid derivatives
EP2805953B1 (en) 2004-12-21 2016-03-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20070269486A1 (en) * 2005-03-14 2007-11-22 Conor Medsystems, Llc. Methods and Devices for Reducing Tissue Damage After Ischemic Injury
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
FR2887442A1 (fr) * 2005-06-28 2006-12-29 Oreal Composes benzyl-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute
FR2887444A1 (fr) * 2005-06-28 2006-12-29 Oreal Composes benzylidene-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute et/ou augmenter leur densite.
KR20080028415A (ko) * 2005-07-12 2008-03-31 다이이찌 산쿄 가부시키가이샤 ＰＰＡＲγ 애고니스트를 함유하는 의약 조성물
CN101374523B (zh) * 2005-09-14 2012-04-11 武田药品工业株式会社 用于治疗糖尿病的二肽基肽酶抑制剂
CA2622642C (en) * 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
TW200730173A (en) * 2005-12-16 2007-08-16 Sankyo Co Pharmaceutical composition enhancing production of adiponectin
AR059790A1 (es) * 2006-03-08 2008-04-30 Medichem Sa Procedimiento para la preparacion de formas polimorficas de 5 - (4 - [2 - (n-metil - n -(2 - piridil)amino)etoxi]benciliden) 2, 4 - tiazolidindiona y una forma polimorfica de maleato de rosiglitazona.
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
WO2007112368A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
CA2647258A1 (en) * 2006-03-31 2007-10-18 Wellstat Therapeutics Corporation Combination treatment of metabolic disorders
DE202006020710U1 (de) 2006-05-09 2009-12-31 Teva Pharmaceutical Industries Ltd. Zusammensetzungen mit Rosiglitazonmaleat
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20070293546A1 (en) * 2006-06-15 2007-12-20 Srinivasula Reddy Maddula Preparation of rosiglitazone and its salts
HUP0600517A3 (en) * 2006-06-23 2008-10-28 Richter Gedeon Nyrt Process for the production of benzylidene-rosiglitazone base
CA2787343C (en) 2006-06-26 2016-08-02 Amgen Inc. Compositions comprising modified lcat and uses thereof
MX2009000439A (es) * 2006-07-14 2009-02-04 Ranbaxy Lab Ltd Formas polimorficas de un inhibidor de hmg-coa reductasa y usos de las mismas.
JP2010502670A (ja) 2006-09-07 2010-01-28 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 真性糖尿病のための組合せ治療
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
KR20170127074A (ko) * 2006-09-13 2017-11-20 다케다 야쿠힌 고교 가부시키가이샤 2-［6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2ｈ-피리미딘-1-일메틸］-4-플루오로-벤조니트릴의 용도
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US20100104636A1 (en) * 2006-12-21 2010-04-29 Panagiotis Keramidas Pharmaceutical Compound and Composition
US20080176905A1 (en) * 2007-01-22 2008-07-24 Santiago Ini Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
CA2677661A1 (en) 2007-02-07 2008-08-14 Kyowa Hakko Kirin Co., Ltd. Tricyclic compounds
US8093236B2 (en) * 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
ES2550479T3 (es) 2007-04-05 2015-11-10 Daiichi Sankyo Company, Limited Derivados de heteroarilo bicíclico condensado
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
PL2489731T3 (pl) 2007-07-26 2015-01-30 Amgen Inc Zmodyfikowane enzymy acylotransferaza lecytyna-cholesterol
US20090076093A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
PL384446A1 (pl) * 2008-02-12 2009-08-17 Adamed Spółka Z Ograniczoną Odpowiedzialnością Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2,4-tiazolidynodionu z kwasem malonowym i sposób jej wytwarzania
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US8486980B2 (en) 2008-08-06 2013-07-16 Kyowa Hakko Kirin Co., Ltd. Tricyclic compound
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
CN104805198B (zh) * 2008-08-12 2019-04-26 金帆德尔制药股份有限公司 鉴定疾病风险因子的方法
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate
US20100144140A1 (en) * 2008-12-10 2010-06-10 Novellus Systems, Inc. Methods for depositing tungsten films having low resistivity for gapfill applications
HUP0800755A2 (en) 2008-12-11 2010-09-28 Richter Gedeon Nyrt Crystalline forms of rosiglitazone
SG172469A1 (en) 2009-03-05 2011-08-29 Daiichi Sankyo Co Ltd Pyridine derivative
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
WO2011120923A1 (en) 2010-03-30 2011-10-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
TW201219353A (en) 2010-09-07 2012-05-16 Daiichi Sankyo Co Ltd Manufacturing method of benzoates
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
EA201691399A1 (ru) 2011-01-10 2016-10-31 Зинфандел Фармасьютикалз, Инк. Способы и готовые лекарственные формы для лечения болезни альцгеймера
US8969345B2 (en) 2011-08-03 2015-03-03 Kyowa Hakko Kirin Co., Ltd. Dibenzooxepin derivative
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
WO2013086443A1 (en) 2011-12-08 2013-06-13 Amgen Inc. Agonistic human lcat antigen binding proteins and their use in therapy
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
CA2890086C (en) 2012-11-05 2022-05-31 Commissariat A L'energie Atomique Et Aux Energies Alternatives (Cea) Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist preferably a thiazolid nedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
EP3065757A4 (en) 2013-10-09 2017-08-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
WO2015068156A1 (en) 2013-11-05 2015-05-14 Ben-Gurion University Of The Negev Research And Development Authority Compounds for the treatment of diabetes and disease complications arising from same
TWI705071B (zh) 2014-10-24 2020-09-21 美商必治妥美雅史谷比公司 經修飾之fgf-21多肽及其用途
US10034868B2 (en) 2014-11-04 2018-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
EP3568134A1 (en) 2017-01-16 2019-11-20 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for reducing cd95- mediated cell motility
GR1010570B (el) * 2022-12-22 2023-11-17 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Α.Β.Ε.Ε., 4-(2-(4-((2,4-διοξοθειαζολιδιν-5-υλ)μεθυλ)φαινοξυ) παραγωγα με δραση αναστολης της αυτοταξινης

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate

Also Published As

Publication number Publication date
KR890005095A (ko) 1989-05-11
NL300034I1 (nl) 2001-03-01
NZ226027A (en) 1992-03-26
CA1328452C (en) 1994-04-12
DE10199003I1 (de) 2003-06-12
HK1011029A1 (en) 1999-07-02
NL300034I2 (nl) 2001-05-01
JPH09183726A (ja) 1997-07-15
PT88410A (pt) 1989-07-31
US5002953A (en) 1991-03-26
JP2614497B2 (ja) 1997-05-28
AU611938B2 (en) 1991-06-27
DE3856378D1 (de) 1999-12-23
DK175176B1 (da) 2004-06-21
JPH09183771A (ja) 1997-07-15
LU90711I2 (fr) 2001-03-05
JP2837139B2 (ja) 1998-12-14
KR0164207B1 (ko) 1999-01-15
PT88410B (pt) 1992-10-30
EP0842925A1 (en) 1998-05-20
JP2817840B2 (ja) 1998-10-30
DK200001556A (da) 2000-10-18
GR3031873T3 (en) 2000-02-29
JPH10194970A (ja) 1998-07-28
IE20000683A1 (en) 2002-07-24
SG59988A1 (en) 1999-02-22
CZ391691A3 (en) 1993-03-17
JPH01131169A (ja) 1989-05-24
DE3856378T2 (de) 2000-05-11
JPH09183772A (ja) 1997-07-15
DK490288D0 (da) 1988-09-02
EP0306228B1 (en) 1999-11-17
AU2173888A (en) 1989-03-09
EP0306228A1 (en) 1989-03-08
ATE186724T1 (de) 1999-12-15
ES2137915T3 (es) 2000-01-01
DK490288A (da) 1989-03-05
JPH10194971A (ja) 1998-07-28

Similar Documents

Publication Publication Date Title
DE10199003I2 (instruction)
GB8919417D0 (en) Novel compounds
GB8919434D0 (en) Novel compounds
HU9500006D0 (en) Heterocyclic compounds as pharmaceutical
TW385309B (en) Novel thiazolidinedione antidiabetic agents
EP0356214A3 (en) Thiazolidine dione derivatives
GB9308487D0 (en) Novel compounds
IL77452A (en) Derivatives of arylcyclobutylalkyl-amines,their preparation and pharmaceutical compositions containing them
NZ231380A (en) Xanthine derivatives and pharmaceutical compositions
DE69625795D1 (de) Thiazolidinedionderivate mit antidiabetischen, hypolipidämischen und antihypertensiven Eigenschaften, Verfahren zu deren Herstellung und pharmazeutischen Zusammenstellungen, die sie enthalten
ATE123487T1 (de) Derivate der kaffeinsäure und sie enthaltende pharmazeutische zusammensetzungen.
ES2023760A6 (es) Procedimiento para la preparacion de derivados benzotiazinicos.